C4 Therapeutics

CCCC64

Penny Stock

$4.25arrow_drop_up6.35%$0.25

Penny Stock

CCCC64

$4.25

arrow_drop_up6.35%$0.25

Penny Stock

Performance History

Key Stats
Open	$4.00
Prev. Close	$4.01
EPS	-1.71
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$300.00M
PE Ratio	-

	LOW	HIGH
Day Range	3.93	4.58
52 Week Range	1.06	11.88

Ratios







EPS	-1.71

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About C4 Therapeutics (CCCC)

C4 Therapeutics Inc (CCCC) is a biotechnology company that is focused on developing a new class of drugs called Targeted Protein Degradation (TPD). TPD is a novel approach to drug discovery that aims to selectively remove disease-causing proteins from cells. The company's platform utilizes small molecules known as Degronimid™ to tag specific proteins for degradation by the cell's own protein recycling machinery. This approach has the potential to address a wide range of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

C4 Therapeutics Inc was founded in 2015 and is headquartered in Watertown, Massachusetts. The company went public in October 2020, raising $172.5 million in its initial public offering (IPO). Since then, its stock price has experienced volatility, reflecting the market's perception of the company's potential and progress. As of the most recent trading session, CCCC stock was trading at $25.60 per share, with a 52-week range between $10.02 and $45.92.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Andrew J. Hirsch M.B.A.
Headquarters: Watertown
Employees: 146
Exchange: NASDAQ

Keep an eye on C4 Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is C4 Therapeutics 's (CCCC) price per share?

The current price per share for C4 Therapeutics (CCCC) is $4.25. The stock has seen a price change of $0.25 recently, indicating a 6.36% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for C4 Therapeutics (CCCC)?

For C4 Therapeutics (CCCC), the 52-week high is $11.88, which is 179.53% from the current price. The 52-week low is $1.06, the current price is 300.94% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is C4 Therapeutics (CCCC) a growth stock?

C4 Therapeutics (CCCC) has shown an average price growth of -3.66% over the past three years. It has received a score of 56 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying C4 Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is C4 Therapeutics (CCCC) stock price performance year to date (YTD)?

As of the latest data, C4 Therapeutics (CCCC) has a year-to-date price change of -34.82%. Over the past month, the stock has experienced a price change of -29.64%. Over the last three months, the change has been -35.99%. Over the past six months, the figure is -23.7%.

help

Is C4 Therapeutics (CCCC) a profitable company?

C4 Therapeutics (CCCC) has a net income of -$132.49M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -183.86% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $20.76M, although specific revenue growth data is currently not available. Operating income is noted at -$139.03M. Furthermore, the EBITDA is -$115.13M.

help

What is the market capitalization of C4 Therapeutics (CCCC)?

C4 Therapeutics (CCCC) has a market capitalization of $300M. The average daily trading volume is 4.25, indicating the stock's liquidity and investor engagement.

News

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

PHASE 1 CLINICAL TRIAL

Sep 8, 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 THERAPEUTICS

INVESTOR CONFERENCES

TARGETED PROTEIN DEGRADATION

Aug 29, 2024

C4 Therapeutics to Participate in Upcoming September Investor Conferences